{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,17]],"date-time":"2025-11-17T17:18:44Z","timestamp":1763399924385,"version":"3.37.3"},"reference-count":38,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2020,7,23]],"date-time":"2020-07-23T00:00:00Z","timestamp":1595462400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2020,7,23]],"date-time":"2020-07-23T00:00:00Z","timestamp":1595462400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Ewha Womans University College of Medicine","award":["the 2017 Young Medical Science Researcher Grants"],"award-info":[{"award-number":["the 2017 Young Medical Science Researcher Grants"]}]},{"name":"Korean Cancer Foundation","award":["K20190517"],"award-info":[{"award-number":["K20190517"]}]},{"DOI":"10.13039\/501100003725","name":"National Research Foundation of Korea","doi-asserted-by":"publisher","award":["No. 2020R1C1C1011369"],"award-info":[{"award-number":["No. 2020R1C1C1011369"]}],"id":[{"id":"10.13039\/501100003725","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>This study aims to investigate the difference of gene expression and its prognostic significance in younger women with melanoma. Significantly upregulated genes in tumors compared to normal skin tissues were extracted. Among these genes, genes that significantly affected survival according to expression level were selected, and pathway annotation was performed. The patient proportion with high\/low expression of the most significant pathways was analyzed in each age (&lt;\u200950, 50\u201359,\u2009\u2265\u200960) and gender group. Survival was analyzed according to age, gender, and pathways. The most significant pathways that were upregulated in tumor tissues and also had impacts on survival were programmed cell death protein [PD]-1, interferon-\u03b3, and interferon-\u03b1\/\u03b2 pathways. In women, the immune signaling rate in patients was higher than men and decreased with age (63.5%, 53.8%, and 47.6%). In men, the decreasing tendency was minimal (47.6%, 50.0%, and 41.6%). In patients aged &lt;\u200960\u00a0years, women had a favorable survival rate than men (<jats:italic>p<\/jats:italic>\u2009=\u20090.055). Except for patients with high immune signaling, no survival difference was observed between genders (<jats:italic>p<\/jats:italic>\u2009=\u20090.6). In conclusion, younger female melanoma patients had high immune signaling than older women and men. This immune signaling improved survival of the younger female patients.<\/jats:p>","DOI":"10.1038\/s41598-020-69082-z","type":"journal-article","created":{"date-parts":[[2020,7,23]],"date-time":"2020-07-23T10:05:06Z","timestamp":1595498706000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":8,"title":["Immune expression signatures as candidate prognostic biomarkers of age and gender survival differences in cutaneous melanoma"],"prefix":"10.1038","volume":"10","author":[{"given":"Yi-Jun","family":"Kim","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kyubo","family":"Kim","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kye Hwa","family":"Lee","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jiyoung","family":"Kim","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wonguen","family":"Jung","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2020,7,23]]},"reference":[{"key":"69082_CR1","doi-asserted-by":"publisher","first-page":"394","DOI":"10.3322\/caac.21492","volume":"68","author":"F Bray","year":"2018","unstructured":"Bray, F. et al. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J. Clin. 68, 394\u2013424. https:\/\/doi.org\/10.3322\/caac.21492 (2018).","journal-title":"CA Cancer J. Clin."},{"key":"69082_CR2","doi-asserted-by":"publisher","first-page":"7","DOI":"10.3322\/caac.21551","volume":"69","author":"RL Siegel","year":"2019","unstructured":"Siegel, R. L., Miller, K. D. & Jemal, A. Cancer statistics, 2019. CA Cancer J. Clin. 69, 7\u201334. https:\/\/doi.org\/10.3322\/caac.21551 (2019).","journal-title":"CA Cancer J. Clin."},{"key":"69082_CR3","doi-asserted-by":"publisher","first-page":"693","DOI":"10.1097\/01.sla.0000216771.81362.6b","volume":"243","author":"CR Scoggins","year":"2006","unstructured":"Scoggins, C. R. et al. Gender-related differences in outcome for melanoma patients. Ann. Surg. 243, 693\u2013700. https:\/\/doi.org\/10.1097\/01.sla.0000216771.81362.6b (2006).","journal-title":"Ann. Surg."},{"key":"69082_CR4","doi-asserted-by":"publisher","first-page":"719","DOI":"10.1038\/jid.2010.354","volume":"131","author":"A Joosse","year":"2011","unstructured":"Joosse, A. et al. Gender differences in melanoma survival: female patients have a decreased risk of metastasis. J. Investig. Dermatol. 131, 719\u2013726 (2011).","journal-title":"J. Investig. Dermatol."},{"key":"69082_CR5","first-page":"1795","volume":"112","author":"K Lasithiotakis","year":"2008","unstructured":"Lasithiotakis, K. et al. Age and gender are significant independent predictors of survival in primary cutaneous melanoma. Cancer Interdiscip. Int. J. Am. Cancer Soc. 112, 1795\u20131804 (2008).","journal-title":"Cancer Interdiscip. Int. J. Am. Cancer Soc."},{"key":"69082_CR6","doi-asserted-by":"publisher","first-page":"S11","DOI":"10.1016\/j.ijwd.2017.02.003","volume":"3","author":"MR Roh","year":"2017","unstructured":"Roh, M. R., Eliades, P., Gupta, S., Grant-Kels, J. M. & Tsao, H. Cutaneous melanoma in women. Int. J. Women\u2019s Dermatol. 3, S11\u2013S15 (2017).","journal-title":"Int. J. Women's Dermatol."},{"key":"69082_CR7","doi-asserted-by":"publisher","first-page":"djv221","DOI":"10.1093\/jnci\/djv221","volume":"107","author":"S Gupta","year":"2015","unstructured":"Gupta, S., Artomov, M., Goggins, W., Daly, M. & Tsao, H. Gender disparity and mutation burden in metastatic melanoma. JNCI J. Natl. Cancer Inst. 107, djv221\u00a0(2015).","journal-title":"JNCI J. Natl. Cancer Inst."},{"key":"69082_CR8","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1186\/s13293-016-0070-1","volume":"7","author":"B Hernando","year":"2016","unstructured":"Hernando, B. et al. Sex-specific genetic effects associated with pigmentation, sensitivity to sunlight, and melanoma in a population of Spanish origin. Biol. Sex Differ. 7, 17 (2016).","journal-title":"Biol. Sex Differ."},{"key":"69082_CR9","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1007\/s12032-016-0868-z","volume":"34","author":"C Oliveira","year":"2017","unstructured":"Oliveira, C., Louren\u00e7o, G. J., Rinck-Junior, J. A., de Moraes, A. M. & Lima, C. S. P. Polymorphisms in apoptosis-related genes in cutaneous melanoma prognosis: sex disparity. Med. Oncol. 34, 19 (2017).","journal-title":"Med. Oncol."},{"key":"69082_CR10","doi-asserted-by":"publisher","first-page":"242","DOI":"10.3390\/ijms19010242","volume":"19","author":"T-A Yuan","year":"2018","unstructured":"Yuan, T.-A. et al. A case-control study of the genetic variability in reactive oxygen species: metabolizing enzymes in melanoma risk. Int. J. Mol. Sci. 19, 242 (2018).","journal-title":"Int. J. Mol. Sci."},{"key":"69082_CR11","doi-asserted-by":"publisher","first-page":"e0170025","DOI":"10.1371\/journal.pone.0170025","volume":"12","author":"A Zainulabadeen","year":"2017","unstructured":"Zainulabadeen, A., Yao, P. & Zare, H. Underexpression of specific interferon genes is associated with poor prognosis of melanoma. PLoS ONE 12, e0170025 (2017).","journal-title":"PLoS ONE"},{"key":"69082_CR12","doi-asserted-by":"publisher","first-page":"351-e1","DOI":"10.1016\/j.ajog.2011.05.014","volume":"205","author":"KK McKnight","year":"2011","unstructured":"McKnight, K. K. et al. Racial and regional differences in age at menopause in the United States: findings from the reasons for geographic and racial differences in stroke (REGARDS) study. Am. J. Obstet. Gynecol. 205, 351-e1 (2011).","journal-title":"Am. J. Obstet. Gynecol."},{"key":"69082_CR13","doi-asserted-by":"publisher","unstructured":"Markman, J., Wakita, D., Crother, T. & Arditi, M.\u00a0Abstract 1459: Revealing the underlying causes of the gender disparity in melanoma: Role of testosterone. Cancer Res. https:\/\/doi.org\/10.1158\/1538-7445.AM2016-1459 (2016).","DOI":"10.1158\/1538-7445.AM2016-1459"},{"key":"69082_CR14","doi-asserted-by":"publisher","first-page":"1763","DOI":"10.1002\/ijc.30878","volume":"141","author":"E Botteri","year":"2017","unstructured":"Botteri, E. et al. Menopausal hormone therapy and risk of melanoma: do estrogens and progestins have a different role?. Int. J. Cancer 141, 1763\u20131770 (2017).","journal-title":"Int. J. Cancer"},{"key":"69082_CR15","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1016\/j.cellimm.2015.01.018","volume":"294","author":"S Kovats","year":"2015","unstructured":"Kovats, S. Estrogen receptors regulate innate immune cells and signaling pathways. Cell. Immunol. 294, 63\u201369 (2015).","journal-title":"Cell. Immunol."},{"key":"69082_CR16","doi-asserted-by":"publisher","first-page":"e1235107","DOI":"10.1080\/2162402X.2016.1235107","volume":"5","author":"JM Obeid","year":"2016","unstructured":"Obeid, J. M. et al. PD-L1, PD-L2 and PD-1 expression in metastatic melanoma: correlation with tumor-infiltrating immune cells and clinical outcome. Oncoimmunology 5, e1235107 (2016).","journal-title":"Oncoimmunology"},{"key":"69082_CR17","doi-asserted-by":"publisher","first-page":"e000150","DOI":"10.1136\/esmoopen-2016-000150","volume":"2","author":"A Kitano","year":"2017","unstructured":"Kitano, A. et al. Tumour-infiltrating lymphocytes are correlated with higher expression levels of PD-1 and PD-L1 in early breast cancer. ESMO Open 2, e000150 (2017).","journal-title":"ESMO Open"},{"key":"69082_CR18","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1016\/j.cell.2017.06.016","volume":"170","author":"CJ Nirschl","year":"2017","unstructured":"Nirschl, C. J. et al. IFN\u03b3-dependent tissue-immune homeostasis is co-opted in the tumor microenvironment. Cell 170, 127\u2013141 (2017).","journal-title":"Cell"},{"key":"69082_CR19","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1186\/s40425-019-0635-8","volume":"7","author":"C Lu","year":"2019","unstructured":"Lu, C. et al. Type I interferon suppresses tumor growth through activating the STAT3-granzyme B pathway in tumor-infiltrating cytotoxic T lymphocytes. J. Immunother. Cancer 7, 157 (2019).","journal-title":"J. Immunother. Cancer"},{"key":"69082_CR20","doi-asserted-by":"publisher","first-page":"2619","DOI":"10.1158\/1078-0432.CCR-10-1114","volume":"17","author":"S Hervas-Stubbs","year":"2011","unstructured":"Hervas-Stubbs, S. et al. Direct effects of type I interferons on cells of the immune system. Clin. Cancer Res. 17, 2619\u20132627 (2011).","journal-title":"Clin. Cancer Res."},{"key":"69082_CR21","doi-asserted-by":"publisher","first-page":"375","DOI":"10.1016\/S1470-2045(15)70076-8","volume":"16","author":"JS Weber","year":"2015","unstructured":"Weber, J. S. et al. Nivolumab versus chemotherapy in patients with advanced melanoma who progressed after anti-CTLA-4 treatment (CheckMate 037): a randomised, controlled, open-label, phase 3 trial. Lancet Oncol. 16, 375\u2013384 (2015).","journal-title":"Lancet Oncol."},{"key":"69082_CR22","doi-asserted-by":"publisher","first-page":"1600","DOI":"10.1001\/jama.2016.4059","volume":"315","author":"A Ribas","year":"2016","unstructured":"Ribas, A. et al. Association of pembrolizumab with tumor response and survival among patients with advanced melanoma. JAMA 315, 1600\u20131609 (2016).","journal-title":"JAMA"},{"key":"69082_CR23","doi-asserted-by":"publisher","first-page":"2521","DOI":"10.1056\/NEJMoa1503093","volume":"372","author":"C Robert","year":"2015","unstructured":"Robert, C. et al. Pembrolizumab versus ipilimumab in advanced melanoma. N. Engl. J. Med. 372, 2521\u20132532 (2015).","journal-title":"N. Engl. J. Med."},{"key":"69082_CR24","doi-asserted-by":"publisher","first-page":"171","DOI":"10.1016\/j.ejca.2017.06.006","volume":"82","author":"NJ Ives","year":"2017","unstructured":"Ives, N. J. et al. Adjuvant interferon-\u03b1 for the treatment of high-risk melanoma: an individual patient data meta-analysis. Eur. J. Cancer 82, 171\u2013183 (2017).","journal-title":"Eur. J. Cancer"},{"key":"69082_CR25","doi-asserted-by":"publisher","first-page":"114","DOI":"10.1097\/CMR.0b013e32835e7713","volume":"23","author":"MR Roh","year":"2013","unstructured":"Roh, M. R. et al. Difference of interferon-\u03b1 and interferon-\u03b2 on melanoma growth and lymph node metastasis in mice. Melanoma Res. 23, 114\u2013124 (2013).","journal-title":"Melanoma Res."},{"key":"69082_CR26","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1016\/S0065-2776(07)96002-2","volume":"96","author":"JR Schoenborn","year":"2007","unstructured":"Schoenborn, J. R. & Wilson, C. B. Regulation of interferon-\u03b3 during innate and adaptive immune responses. Adv. Immunol. 96, 41\u2013101 (2007).","journal-title":"Adv. Immunol."},{"key":"69082_CR27","doi-asserted-by":"publisher","first-page":"436","DOI":"10.1158\/0008-5472.CAN-17-1615","volume":"78","author":"X Mo","year":"2018","unstructured":"Mo, X. et al. Interferon-\u03b3 signaling in melanocytes and melanoma cells regulates expression of CTLA-4. Can. Res. 78, 436\u2013450 (2018).","journal-title":"Can. Res."},{"key":"69082_CR28","doi-asserted-by":"publisher","first-page":"397","DOI":"10.1016\/j.cell.2016.08.069","volume":"167","author":"J Gao","year":"2016","unstructured":"Gao, J. et al. Loss of IFN-\u03b3 pathway genes in tumor cells as a mechanism of resistance to anti-CTLA-4 therapy. Cell 167, 397\u2013404 (2016).","journal-title":"Cell"},{"key":"69082_CR29","doi-asserted-by":"publisher","first-page":"1189","DOI":"10.1016\/j.celrep.2017.04.031","volume":"19","author":"A Garcia-Diaz","year":"2017","unstructured":"Garcia-Diaz, A. et al. Interferon receptor signaling pathways regulating PD-L1 and PD-L2 expression. Cell Rep. 19, 1189\u20131201 (2017).","journal-title":"Cell Rep."},{"key":"69082_CR30","doi-asserted-by":"publisher","first-page":"188","DOI":"10.1158\/2159-8290.CD-16-1223","volume":"7","author":"DS Shin","year":"2017","unstructured":"Shin, D. S. et al. Primary resistance to PD-1 blockade mediated by JAK1\/2 mutations. Cancer Discov. 7, 188\u2013201 (2017).","journal-title":"Cancer Discov."},{"key":"69082_CR31","doi-asserted-by":"publisher","first-page":"319","DOI":"10.1038\/nbt.3838","volume":"35","author":"L Collado-Torres","year":"2017","unstructured":"Collado-Torres, L. et al. Reproducible RNA-seq analysis using recount2. Nat. Biotechnol. 35, 319 (2017).","journal-title":"Nat. Biotechnol."},{"key":"69082_CR32","doi-asserted-by":"publisher","first-page":"e1006701","DOI":"10.1371\/journal.pcbi.1006701","volume":"15","author":"M Mounir","year":"2019","unstructured":"Mounir, M. et al. New functionalities in the TCGAbiolinks package for the study and integration of cancer data from GDC and GTEx. PLoS Comput. Biol. 15, e1006701 (2019).","journal-title":"PLoS Comput. Biol."},{"key":"69082_CR33","doi-asserted-by":"publisher","first-page":"e71","DOI":"10.1093\/nar\/gkv1507","volume":"44","author":"A Colaprico","year":"2015","unstructured":"Colaprico, A. et al. TCGAbiolinks: an R\/Bioconductor package for integrative analysis of TCGA data. Nucleic Acids Res. 44, e71\u2013e71 (2015).","journal-title":"Nucleic Acids Res."},{"key":"69082_CR34","doi-asserted-by":"publisher","first-page":"1184","DOI":"10.1038\/nprot.2009.97","volume":"4","author":"S Durinck","year":"2009","unstructured":"Durinck, S., Spellman, P. T., Birney, E. & Huber, W. Mapping identifiers for the integration of genomic datasets with the R\/Bioconductor package biomaRt. Nat. Protoc. 4, 1184 (2009).","journal-title":"Nat. Protoc."},{"key":"69082_CR35","volume-title":"Modeling Survival Data: Extending the Cox Model","author":"TM Therneau","year":"2013","unstructured":"Therneau, T. M. & Grambsch, P. M. Modeling Survival Data: Extending the Cox Model (Springer, Berlin, 2013)."},{"key":"69082_CR36","unstructured":"Kassambara, A., Kosinski, M., Biecek, P. & Fabian, S. Package \u2018survminer\u2019. https:\/\/cran.r-project.org\/web\/packages\/survminer\/survminer.pdf\u00a0(2017)."},{"key":"69082_CR37","doi-asserted-by":"publisher","first-page":"1846","DOI":"10.1093\/bioinformatics\/btm254","volume":"23","author":"S Davis","year":"2007","unstructured":"Davis, S. & Meltzer, P. S. GEOquery: a bridge between the Gene Expression Omnibus (GEO) and BioConductor. Bioinformatics 23, 1846\u20131847 (2007).","journal-title":"Bioinformatics"},{"key":"69082_CR38","unstructured":"Dunning, M., Lynch, A. & Eldridge, M. illuminaHumanv4.db: Illumina HumanHT12v4 annotation data (chip illuminaHumanv4). R package version 1 (2015)."}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-020-69082-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-020-69082-z","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-020-69082-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,12,6]],"date-time":"2022-12-06T14:23:01Z","timestamp":1670336581000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-020-69082-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,7,23]]},"references-count":38,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2020,12]]}},"alternative-id":["69082"],"URL":"https:\/\/doi.org\/10.1038\/s41598-020-69082-z","relation":{},"ISSN":["2045-2322"],"issn-type":[{"type":"electronic","value":"2045-2322"}],"subject":[],"published":{"date-parts":[[2020,7,23]]},"assertion":[{"value":"26 December 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 May 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 July 2020","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"12322"}}